ANTHONY LUCCI to Triple Negative Breast Neoplasms
This is a "connection" page, showing publications ANTHONY LUCCI has written about Triple Negative Breast Neoplasms.
Connection Strength
1.983
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer. 2024 Aug 16; 24(1):1016.
Score: 0.455
-
Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016; 11(7):e0159072.
Score: 0.259
-
Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S552-8.
Score: 0.239
-
Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents. PLoS One. 2014; 9(10):e109487.
Score: 0.230
-
Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):325-33.
Score: 0.228
-
Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
Score: 0.103
-
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524.
Score: 0.100
-
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis Oncol. 2022 03; 6:e2000368.
Score: 0.096
-
Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol. 2021 Oct; 28(10):5626-5634.
Score: 0.092
-
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
Score: 0.092
-
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg. 2018 04; 105(5):535-543.
Score: 0.073
-
Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66.
Score: 0.016